Cleveland Clinic-led research has identified geographic areas in the United States where strategic efforts to promote colorectal cancer screening could help reduce health care gaps affecting Hispanic/Latino communities.
Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.
